We advised
- Acerta Pharma on its acquisition by AstraZeneca for up to USD 7 billion
- Arvelle Therapeutics in its USD 180 million (€159.1m) Series A
- ASIT biotech with its business combination with DMS Imaging and capital increase.
- Avania Group with the sale of a majority stake in Avania to Astorg
- Cerba Healthcare on its acquisition of Viroclinics
- Batavia Biosciences on its auction sale to CJ Corp
- Dezima Pharma on its up to 1.5 billion acquisition by Amgen
- Eagle Pharmaceuticals on the acquisition of Acacia Pharma Group plc.
- Fysicon on its acquisition by Canon Medical Systems Cooperation
- Getinge on its acquisition of Applikon Biotechnology
- Gingko Bioworks on its acquisition of Dutch DNA
- InflaRx in its listing on NASDAQ
- Keensight Capital on the acquisition of Symeres
- Lava Therapeutics on listing on NASDAQ
- Lumick’s Technologies on its Series D round
- Mediq with the acquisition of Remedus.
- Mylan in its USD 22 billion merger with Pfizer’s spin-out Upjohn, its EUR 30 billion unsolicited voluntary public offer for Perrigo Company plc, as well as assisting Mylan in its pending USD 7.5 million bid for Meda
- Neogene Therapeutics on its sale to AstraZeneca
- NewAmsterdam Pharma on its business combination with Frazier Healthcare
- Pharming Group with its public company work
- Rhythm Pharmaceutical on its acquisition of Xinvento
- S-Biomedic on the sale of a majority stake to Beiersdorf.
- Sanofi on its acquisitions of Kiadis Pharma and Ablynx
- Siemens Healthineers on its strategic collaboration with Screenpoint Medical
- Suazio on the sale of their shares to NAMSA.
- Synaffix on its sale to Lonza Group Ag
- Staten Biotechnology on the collaboration with Novo Nordisk
- VarMx on its seed- and series A and B investments
- VIB, since end 2012, NautaDutilh is the preferred legal partner of VIB
- Vico Therapeutics Holding BV with its EUR 27 million Series A financing round.
- Wacker on its acquisition of Synco BioPartners